肝、脊柱或淋巴结立体定向放疗局部控制的递归分割分析
本研究基于单机构397次针对肝、脊柱和淋巴结的SBRT治疗数据,利用递归分割分析(RPA)建立局部控制风险分层模型。361次治疗纳入局部控制分析,2年局部控制率为71%。RPA将患者分为3类,3年局部控制率分别为29%、50%和83%,治疗靶点和原发肿瘤是局部控制的关键决定因素。
要点
- RPA模型将SBRT患者分为3类,3年局部控制率分别为29%、50%、83%。
- 非小细胞肺癌(NSCLC)原发且靶点非颈胸腰椎者局部失败风险最高。
- 淋巴结靶点和乳腺或卵巢原发肿瘤者局部控制较好。
核心结论
- 针对转移性病灶SBRT的局部控制风险分层模型已建立,治疗靶点和原发肿瘤是局部控制的关键因素。
研究设计与样本
- 单机构数据库纳入397次针对肝、脊柱和淋巴结的SBRT治疗,所有治疗均有影像学随访评估局部控制。
- 采用Cox比例风险分析后进行决策树分析,数据按70%训练集、10%验证集、20%测试集划分以优化RPA模型。
主要发现
- 361次治疗纳入局部控制分析,2年局部控制率为71%。
- 决策树模型在验证集的保真度为93.10%,测试集为87.67%。
- RPA 3类为NSCLC原发且靶点非颈、胸、腰椎者,RPA 2类为原发非NSCLC或乳腺且靶点为骶椎或肝脏者。
- RPA 1类包括所有其他患者(含淋巴结靶点和乳腺原发者),3类、2类、1类的3年局部控制率分别为29%、50%、83%。
- 亚组分析显示淋巴结靶点较其他靶点局部控制改善(P < .005),卵巢原发疾病较其他原发部位局部控制改善(P < .005)。
关键数值与推荐
- RPA 3类:NSCLC原发且治疗靶点非颈、胸、腰椎,3年局部控制率29%。
- RPA 2类:原发非NSCLC或乳腺且靶点为骶椎或肝脏,3年局部控制率50%。
- RPA 1类:其他患者(含淋巴结靶点和乳腺原发),3年局部控制率83%。
临床怎么用
- 可依据原发肿瘤类型和SBRT靶点进行局部控制风险分层,辅助临床决策。
- 对NSCLC原发且靶点非脊柱者需关注较高局部失败风险。
- 淋巴结靶点和乳腺或卵巢原发者局部控制较好。
局限性
- 单机构回顾性数据库,样本量有限。
- 模型需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to develop a local control risk stratification using recursive partitioning analysis (RPA) for patients receiving stereotactic body radiation therapy (SBRT) for metastatic cancer. METHODS AND MATERIALS: A single institutional database of 397 SBRT treatments to the liver, spine, and lymph nodes was constructed. All treatments required imaging follow-up to assess for local control. Cox proportional hazards analysis was implemented before the decision tree analysis. The data were split into training (70%), validation (10%), and testing (20%) sets for RPA to optimize the training set. RESULTS: In the study, 361 treatments were included in the local control analysis. Two-year local control was 71%. A decision tree analysis was used and the resulting model demonstrated 93.10% fidelity for the validation set and 87.67% for the test set. RPA class 3 was composed of patients with non-small cell lung cancer (NSCLC) primary tumors and treatment targets other than the cervical, thoracic, and lumbar spines. RPA class 2 included patients with primary cancers other than NSCLC or breast and treatments targets of the sacral spine or liver. RPA class 1 consisted of all other patients (including lymph node targets and patients with primary breast cancer). Classes 3, 2, and 1 demonstrated 3-year local controls rates of 29%, 50%, and 83%, respectively. On subgroup analysis using the Kaplan-Meier method, treatments for lymph nodes and primary ovarian disease demonstrated improved local control relative to other treatment targets (P < .005) and primary disease sites (P < .005), respectively. CONCLUSIONS: A local control risk stratification model for SBRT to sites of metastatic disease was developed. Treatment target and primary tumor were identified as critical factors determining local control. NSCLC primary lesions have increased local failure for targets other than the cervical, thoracic, or lumbar spines, and improved local control was identified for lymph node sites and breast or ovarian primary tumors.
引用
- Kowalchuk RO, Waters MR, Dutta SW, et al. Recursive Partitioning Analysis for Local Control Achieved With Stereotactic Body Radiation Therapy for the Liver, Spine, or Lymph Nodes. Adv Radiat Oncol. 2020. PMID: 34195484. doi:10.1016/j.adro.2020.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。